Compare Davita Inc (DVA) vs Nasdaq100 ETF (QQQ) Price & Performance

Davita IncTrade

Nasdaq100 ETFTrade

Price performance (Past 24H)

Key statistics

Davita Inc vs Nasdaq100 ETF — how do they compare? Davita Inc trades at $179.02 (market cap $11.72B), while Nasdaq100 ETF trades at $723.18. The key difference: Nasdaq100 ETF is trading nearer its 52-week high, Davita Inc nearer its low. Which is the better fit depends on your goals.

	DVA	QQQ
Market Cap	$11.72B	—
Sector	Health	—
52-Week High	$240.96	$746.16
52-Week Low	$103.87	$558.34
Enterprise Value	$24.44B	—

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Davita Inc

DaVita (DVA) trades at $183.77, up 1.72% today, with a mixed technical picture showing bearish moving averages but bullish oscillators. The company reported strong Q2 2026 earnings of $4.02 per share, beating estimates, driven by volume growth. Revenue reached $13.64 billion in 2025, with a net income margin of 6.05%. Analyst consensus is a Buy with a $232.25 price target, though technical signals are bearish overall.

The outlook for DVA is cautiously optimistic, supported by earnings beats and volume growth, but risks include reimbursement pressure and high debt levels. The stock offers potential upside to the consensus target, yet investors face headwinds from margin compression and technical bearishness.

Nasdaq100 ETF

QQQ trades at $723.03, up 1.17% with strong bullish momentum from moving averages and institutional buying interest. The ETF shows technical strength with a bullish overall signal, though RSI_6 at 88.85 indicates potential near-term overbought conditions. Recent news highlights ongoing institutional accumulation and positive momentum in Nasdaq-100 components.

Outlook remains positive given strong technical momentum and institutional support, though elevated short-term RSI suggests potential consolidation. Key risks include expense ratio comparisons with QQQM and tech sector concentration. Analyst consensus is divided with 50% buy and 50% sell ratings.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

DVA

Berkshire Hathaway cuts cash reserves, boosts stock buybacks and equity investments under new CEO Greg Abel.CNBC · 3 days agoBullish View details →

QQQ

JEPQ’s high yield comes with costly ordinary income taxes and capped gains, hurting taxable investors.24/7 Wall Street · 15 hours agoBearish Invesco QQQ ETF costs more than its cheaper clone QQQM despite identical holdings.24/7 Wall Street · 1 day agoNeutral JPMorgan's JEPQ ETF offers Nasdaq exposure with monthly income and less volatility.24/7 Wall Street · 3 days agoNeutral View details →

About Davita Inc

DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.

About Nasdaq100 ETF

The ETF is designed to track the performance of the securities and the stocks in the NASDAQ-100 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.